[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597596":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":7,"locations":13,"responsibleParty":37,"collaborators":39,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":7,"eligibilityCriteria":48,"healthyVolunteers":45,"sex":49,"minAge":50,"maxAge":7,"enrollmentInfo":51,"targetDuration":7,"studyType":54,"phases":7,"briefSummary":55,"conditions":56,"keywords":7,"overallStatus":16,"whyStopped":7,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"HepQuant, LLC","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DEVICE","HepQuant DuO Test","HepQuant DuO is commercially available in the U.S. as a Laboratory Developed Test (LDT), but it will be used in this study as a nonsignificant risk investigational device to measure change in liver function over time.",[14],{"facility":15,"status":16,"city":17,"state":18,"zip":19,"country":20,"countryCode":21,"cosmosGeoPoint":22,"geoPoint":27,"contacts":28},"Stanford University Dept. of Medicine -Gastroenterology & Hepatology","RECRUITING","Redwood City","California","94063","United States","US",{"type":23,"coordinates":24},"Point",[25,26],-122.23635,37.48522,{"lat":26,"lon":25},[29,34],{"name":30,"role":31,"phone":32,"phoneExt":7,"email":33},"Ethan Assistant Clinical Research Coordinating Associate, BA","CONTACT","650-460-6119","eakamaga@stanford.edu",{"name":35,"role":36,"phone":7,"phoneExt":7,"email":7},"Allison Kwong, MD","PRINCIPAL_INVESTIGATOR",{"type":38,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[40],{"name":41,"class":42},"Leland Stanford Junior University","UNKNOWN","100597596","investigating-hepquant-duo-test-as-a-biomarker-in-alcohol-related-liver-disease-100597596",false,"NCT07060547","Investigating HepQuant DuO Test as a Biomarker in Alcohol-related Liver Disease","Inclusion Criteria:\n\n* adult with a clinical diagnosis of liver disease due to alcohol who have acute hepatic decompensation.\n\nadult with a combined clinical diagnosis of alcohol-related liver disease (ALD) and nonalcoholic steatohepatitis (NASH).\n\nExclusion Criteria:\n\n* Clinical diagnosis of liver disease with an etiology other than alcohol liver disease unless it is a combined clinical diagnosis of ALD and NASH.\n* patients with solid organ malignancy.\n* patients with other disease affecting the liver including autoimmune, drug-related liver injury, hemochromatosis or Wilson's disease\n* pregnancy\n* under the age of 18","ALL","18 Years",{"count":52,"type":53},40,"ESTIMATED","OBSERVATIONAL","This is a study to measure liver recovery in patients with recent alcohol-associated liver injury by assessing liver function and physiology using HepQuant DuO. The HepQuant DuO Test is a blood-based test that involves a drink of a natural compound, cholate, and 2 blood samples at 20 and 60 minutes. The study team is collecting clinical and laboratory data to better monitor and treat patients who have been affected by alcohol-associated liver disease. The study has 4 visits at an outpatient clinic at 1, 3, 6, and 12 months. At each of these visits, participants will undergo a HepQuant DuO test and other standard tests. In addition, the study team will ask about a participant's alcohol use, symptoms, and quality of life.",[57,58],"Alcoholic Hepatitis","Alcohol-related Liver Disease","2025-07-01",{"date":61,"type":62},"2025-07-11","ACTUAL",{"date":64,"type":62},"2025-06-10",{"date":66,"type":53},"2032-03",{"name":5,"class":6},1]